(VIANEWS) – Shares of Alnylam Pharmaceuticals (NASDAQ Composite: ALNY) fell 7.14% to $180.00 at 10:17 EST on Tuesday, after three consecutive sessions in a row of gains. NASDAQ Composite is jumping 1.02% to $14,896.85, after five successive sessions in a row of losses. This seems, up until now, an all-around up trend exchanging session today.
Alnylam Pharmaceuticals’s last close was $193.85, 7.57% below its 52-week high of $209.73.
Today’s last reported volume for Alnylam Pharmaceuticals is 441773 which is 29.52% below its average volume of 626893.
Alnylam Pharmaceuticals’s Sales
Alnylam Pharmaceuticals’s sales growth is 74.6% for the current quarter and 46.7% for the next. The company’s growth estimates for the ongoing quarter and the next is 28% and 23.9%, respectively.
Alnylam Pharmaceuticals’s Revenue
Year-on-year quarterly revenue growth grew by 112.1%, now sitting on 687.53M for the twelve trailing months.
Alnylam Pharmaceuticals’s last week, last month’s, and last quarter’s current volatility was a positive 0.59%, a negative 0.90%, and a positive 1.63%, respectively.
Alnylam Pharmaceuticals’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.30% (last week), 1.87% (last month), and 1.63% (last quarter), respectively.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
Alnylam Pharmaceuticals’s stock is considered to be oversold (<=20).
Alnylam Pharmaceuticals’s Stock Yearly Top and Bottom Value
Alnylam Pharmaceuticals’s stock is valued at $180.00 at 10:17 EST, way under its 52-week high of $209.73 and way above its 52-week low of $119.29.
Alnylam Pharmaceuticals’s Moving Average
Alnylam Pharmaceuticals’s value is below its 50-day moving average of $194.92 and above its 200-day moving average of $164.13.
More news about Alnylam Pharmaceuticals (ALNY).